Home > Services > Clinical Research Studies > Clinical Trials Details
<< Back to Results
Phase 2 clinical trial to evaluate the safety and efficacy of IPI-145 as a monotherapy in subjects with iNHL (Follicular Lymphoma, Marginal Zone Lymphoma, or Small Lymphocytic Lymphoma) that is refractory to rituximab and to either chemotherapy or RIT.
Essentia Health Duluth
For more information about a financial conflict of interest (FCOI) or to review the Essentia Health FCOI policy, click here.